Kornimate/medical-research-clean huggingface dataset:
chronic kidney disease patient in chronic myloied leukemia

Conditions: Chronic Myeloid Leukemia in Remission

Summary: to study the prevalence ,characteristics and outcome of ckd in patiants with chronic myeloid leukemia .

* chronic myeloid leukemia (cml) is a cancer of bone marrow that leads to an increased number of white blood cells. cml is more prevalent in the elderly and is characterized by weight loss, tiredness, shortness of breath, excessive sweating, bone pain, and frequent infections. \[1\] according to the american cancer society's estimates, cml represents 15% of all new leukemia cases.\[2\] the global burden of disease (gbd) study 2015 revealed that leukemia was under the top ten leading causes of death globally.\[3\] however, the latest gbd study found a decrease in the age-standardized incidence rate and the death rate from 1990-2017.\[4\] this dramatic improvement in the overall survival and health-related quality of life among cml patients was attributed to the impact of new therapeutic strategies. tyrosine kinase inhibitors (tkis), particularly imatinib, emerged as a potential therapeutic agent for the treatment of cml, reducing epidemiological burden (incidence rate), and improve quality of life.\[5\] * the definition and classification of chronic kidney disease (ckd) have evolved over time, but current international guidelines define this condition as decreased kidney function shown by glomerular filtration rate (gfr) of less than 60 ml/min per 1•73 m2, or markers of kidney damage, or both, of at least 3 months duration, regardless of the underlying cause\[6\] diagnosis is commonly made after chance findings from screening tests (urinary dipstick or blood tests), or when symptoms become severe. the best available indicator of overall kidney function is gfr, which is measured either via exogenous markers (eg, dtpa, iohexol), or estimated using equations. presence of proteinuria is associated with increased risk of progression of ckd and death. presence of proteinuria is associated with increased risk of progression of ckd and death.\[7,8\] kidney biopsy samples can show definitive evidence of ckd, through common changes such as glomerular sclerosis, tubular atrophy, and interstitial fibrosis. complications include anaemia due to reduced production of erythropoietin by the kidney; reduced red blood cell survival and iron deficiency; and mineral bone disease caused by disturbed vitamin d, calcium, and phosphate metabolism.\[9

Eligibility criteria:
inclusion criteria:1_ chronic myloid leukemia patiants who diagonised by biopsy , 2_ cbc. - exclusion : 1_pts known to have ckd before diagnosed of cml. 2- known diabetic pts 3-imaging suggestive ckd etiology rather than cml effect eg.pkd,renal stones,chronic pyelonephritis
short and long term effects of iastm and eswt therapy in individuals with lateral epicondylitis

Conditions: Lateral Epicondylitis

Summary: pain, decreased grip strength, and loss of function are observed in individuals with lateral epicondylitis. the aim of this study is to investigate the effects of eswt and iastm applications on pain, grip strength and function in individuals with lateral epicondylitis.

the study will be carried out on volunteers after the approval of the ethics committee. before the research, individuals and / or their relatives will be informed about the purpose and content of the study. participants will be randomly divided into three groups: iastm, eswt and home exercise group. in addition to home exercise, iastm and eswt groups will be given 2 sessions per week for 4 weeks. pain, grip strength and functionality of the participants will be evaluated before the application, after 4 weeks of application and 4 weeks after the end of the application.

Eligibility criteria:
inclusion criteria: * being diagnosed with chronic let by a physician * visual analog scale (vas) pain score ≥ 3 exclusion criteria: * any accompanying pathology in the wrist and forearm, such as a fracture or dislocation of the elbow; * treatment with corticosteroid injections in the past 6 months

Keywords: lateral epicondylitis pain function grip strength
diagnostic accuracy of doppler ultrasound and role of uterine artery doppler

Conditions: Placenta Accreta

Summary: this study will be conducted on (100) pregnant women diagnosed as placenta previa by ultrasonography and are candidates for either emergency or elective repeated cesarean section or hysterectomy (if the diagnosis of placenta accreta is confirmed). all of those patients are presenting during the period of may 2018 to july 2018 to kasr-al ainy obstetrics outpatient clinic or casualty department during their 3rd trimester. all of them will be assorted according to certain inclusion and exclusion criterions as follow:

this study will be conducted on (100) pregnant women diagnosed as placenta previa by ultrasonography and are candidates for either emergency or elective repeated cesarean section or hysterectomy (if the diagnosis of placenta accreta is confirmed). those patients are attending to kasr-al ainy obstetrics outpatient clinic or casualty department during their 3rd trimester. ultrasound and doppler will be done to all patients to diagnose placenta accreta . the diagnosis will be confirmed by intraoperative assessments and histopathological examination of the uterus after cesarean hysterectomy

Eligibility criteria:
criteria:inclusion criteria * gestational age more than 28 weeks * single living fetus. * one or more cesarean section or hysterotomy. * placenta previa (all grades) with high possibility of morbidly adherent placenta accreta (all types). exclusion criteria: * maternal chronic medical disorder (diabetes mellitus or hypertension). * pregnancy induced disorders (pre-eclampsia or gestational diabetes). * associated fetal anomalies.
population pharmacokinetic (pk) study of multiple doses of cubicin® (daptomycin) 10 mg/kg in critical care patients having bacteremia, endocarditis or skin soft tissue infections due to gram positive bacteria with various degrees of renal failure

Conditions: Renal Failure; Critical Care; Gram Positive Bacteria

Summary: treatment of infections in critically ill patients remains a significant challenge to intensivists world-wide with persisting high mortality and morbidity. compelling evidence suggests that source control of the pathogen and appropriate antibiotic therapy remain the most important interventions to improve patients' outcome, the latter including the administration of a suitable molecule at an optimized dosage regimen. daptomycin is the first representative of a new family of antibiotics, the cyclic lipopeptides. its bactericidal effect against gram-positive bacteria, including meticillin-resistant strains, and its low renal toxicity, make it a useful antibiotic in critically ill patients having infections due to resistant gram positive strains. unfortunately, no pk study has been performed in infected critically ill patients without renal replacement therapy. a vast array of pathophysiological changes can occur in infected critically ill patients, leading to changes in volume of distribution and clearance of antibiotics in these patients, which may affect the antibiotic concentration at the target site. it is therefore important to better characterize daptomycin pk in infected patients with various degrees of renal failure in order to define optimal dosing regimens. this project aims to identify optimal daptomycin administration schemes in critical care patients with various degrees of renal impairment


Eligibility criteria:
inclusion criteria: * patients of two sexes aged 18 to 85 years, * hospitalized in one of the intensive care unit participating in the study, * under mechanical ventilation, * having skin or soft tissue infection, bacteremia or endocarditis caused by gram positivebacteria susceptible to daptomycin, * having given written consent to participate to the study. * patients with severe sepsis and septic shock will also be included because it's the very population that may benefit from daptomycin treatment and it's important to get data for these patients in order to optimize their treatment. exclusion criteria: * pregnant or lactating women * obese subjects (body mass index \> 40 mg/m2) * patients requiring extrarenal replacement therapy, * patients having already received daptomycin during the 21 days prior to inclusion, * known hypersensitivity to daptomycin, * history of myopathy * creatine phosphokinase \>5 upper limit of normal * patients not affiliated to a social security scheme,patients deprived of their liberty by judicial or administrative decision

Keywords: pharmacokinetics
trial of anti-pd-1 immunotherapy and stereotactic radiation in patients with recurrent glioblastoma

Conditions: Glioblastoma Multiforme

Summary: the purpose of this study is to assess the safety/tolerability/feasibility of pembrolizumab and radiation therapy before surgical resection in patients with recurrent glioblastoma as defined by treatment-related aes and the number of patients who do not necessitate a delay in surgical resection, and to assess overall survival. the secondary objectives are to assess progression free survival, and to assess the t cell clonality, cd8 t cell activation and tumor infiltrating lymphocyte (til) score after treatment


Eligibility criteria:
inclusion criteria: * age 18 years or older * confirmed histologic diagnosis of who grade iv, glioblastoma multiforme * gbm recurrence or progression with planned standard of care surgical resection and repeat radiation * tumor size less than 6 cm * ecog performance status of 0-1 * adequate laboratory values exclusion criteria: * contraindication to additional radiation * prior therapy with an anti-pd-1, anti-pd-l1, or anti-pd-l2 agent or with an agent directed to another stimulatory or co-inhibitory t-cell receptor * immunodeficiency diagnosis or receiving chronic systemic steroid therapy (exceeding 10 mg daily of prednisone) or any other form of immunosuppressive therapy * severe hypersensitivity to pembrolizumab complete inclusion/exclusion criteria are detailed in the protocol.

Keywords: central nervous system tumor neurosurgery brain tumor spinal cord tumor surgical resection glioma glioblastoma neuropathology maximal safe resection cns
an observational study of avastin (bevacizumab) in patients with metastatic colorectal cancer in italy (beware)

Conditions: Colorectal Cancer

Summary: this observational, multicenter, retrospective/prospective study will evaluate the use of avastin (bevacizumab) in clinical practice in patients with metastatic colorectal cancer. patients having initiated first-line treatment with a fluoropyrimidine-based chemotherapy and avastin will be followed for up to 15 months.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * metastatic colorectal cancer * having initiated first-line treatment with fluoropyrimidine-based chemotherapy plus avastin between 1. september 2011 and 29. february 2012 * availability of test fro k-ras genotyping exclusion criteria: * participation in a clinical trial during treatment with avastin
prevalence of sleep disturbances in psoriasis

Conditions: Psoriasis

Summary: the purpose of this study is to compare the sleep quality of patients with psoriasis to patients without psoriasis.

in psoriasis, the burden of disease extends well beyond physical manifestations and can be associated with significant physical, social and psychological impairments. the impact of psoriasis on quality of life has been extensively investigated and demonstrates a negative affect on activities of daily living including sleep. sleep abnormalities have also been reported in other dermatologic diseases including atopic dermatitis. however, there is relatively little data on the impact of psoriasis on sleep quality and what factors are likely to cause sleep disturbances. obtaining this information is important because both psoriasis and sleep disorders are associated with cardiovascular disease. a better understanding of sleep problems in psoriasis may help to further our knowledge of psoriasis co-morbidities. certain factors associated with psoriasis, including pruritus, depression, and sleep-disordered breathing (obstructive sleep apnea) can independently affect sleep. it would be of particular interest to assess the effect of these factors on sleep quality in psoriasis subjects and the control group to determine what type of sleep problems exist among patients with psoriasis. this study involves the use of six questionnaires to be given to subjects with psoriasis covering \>10% bsa and 40 subjects without psoriasis matched for age, gender and bmi, as a control population. the questionnaires will be given to subjects when they come for their scheduled appointments. the surveys will be completed anonymously and will be collected by a staff member when they are done. a physician will determine the participants' disease severity using the psoriasis area and severity index (pasi) and will attach the score to their questionnaire. the questionnaires will cover sleep quality, depression, pruritis, insomnia, hypersomnia, and sleep-disordered breathing. subjects will be given standard instructions to follow written directions on each questionnaire and will be given an unlimited amount of time to complete the surveys.

Eligibility criteria:
inclusion criteria: * chronic plaque psoriasis (at least 6 months) exclusion criteria: * active depression

Keywords: dermatology skin psoriasis sleep wake forest insomnia
pilot - peri-operative beta blockade

Conditions: Adrenergic Beta-Receptor Blockader; Troponin Levels; Cardiomyopathy, Post-surgical

Summary: perioperative cardiac adverse events \[heart injuries caused by general anesthesia and surgical procedures\] are a significant public health issue, with more than 60,000 deaths per annum in patients having surgery for non-heart related issues. there are virtually no evidence-based medical strategies for effective prevention of these events. preoperative drug treatment with beta blockade drugs used for high blood pressure, perioperative therapy with lipid lowering drugs such as statins, alpha-receptor agonists such as clonidine used for high blood pressure, and aspirin have all been investigated as potential mitigating treatments, but without positive clinical outcomes and, in some cases, creating more hemodynamic instabilities that result in heart injury. in light of this, investigators propose to evaluate the safety and efficacy of using increasing doses of beta blockade drugs immediately after surgery and to assess the value of high-sensitivity cardiac troponin level testing of the blood in predicting those patients who would benefit most from perioperative beta blocker therapy.


Eligibility criteria:
inclusion criteria: * age \>50 years * american society of anesthesiologists (asa) risk status iii-iv * revised cardiac risk index ≥2 * β-blocker naïve (not having received β-blocker within 30 days prior to surgery) * previously diagnosed coronary artery disease (cad) or at high risk for cad: * history of peripheral vascular disease, or * diabetes and currently on oral anti-diabetic drug or insulin therapy, or * chronic renal failure (egfr \<30 m/min) * major non-cardiac surgery under general anesthesia exclusion criteria: * history of stroke * heart rate \<55bpm * heart failure * second or third degree av block without pacemaker * active asthma or copd * anemia \[hb\<9g/dl\] * allergy to beta-blockade drugs * hemodynamic instability * uncontrolled hemorrhage * unwilling or unable to give consent for participation
prevalence of sarcopenia in geriatric patients

Conditions: Sarcopenia

Summary: to assess the prevalence of sarcopenia among inpatients on acute geriatrics and geriatric rehabilitation wards of a swiss university department of geriatric medicine using the most recent diagnosis definitions from european guidelines.


Eligibility criteria:
inclusion criteria: - all patients \>65 years old admitted to acute geriatrics and geriatric rehabilitation at the study site exclusion criteria: * lack of informed written consent * implanted defibrillation device * acute sepsis, severe volume overload or dehydration * life expectancy of \< 3 months according to treating physician * unremovable bandages * patients in isolation rooms on the ward * measurement is not possible due to organizational reasons * inability to follow the procedures, e.g. due to language problems, psychological disorders

Keywords: prevalence sarcopenia geriatric
effects of gum disease treatment on host defense factors

Conditions: Periodontitis; Diabetes Mellitus

Summary: human immune system produces many different factors, which will influence health-disease statuses. this partially explains why under similar conditions only some people become sick. therefore, specific analyses of such factors in healthy and diseased patients are crucial for a better knowledge about diseases development and successful treatments. human beta defensins (hbd) may have a key role in patient's susceptibility to gum diseases. in the lab, high levels of sugar (glucose) could inhibit their expression and contribute to the occurrence of infections associated with diabetic wounds. this study will evaluate if treatment of the most common gum disease in adults influences production of beta defensins by gingiva. also, clinical improvements and treatment effects on blood glycemic levels will be monitored throughout a 2-month period. patients with or without gum diseases and with or without diabetes mellitus will be able to participate. after a complete oral examination to determine periodontal status, gingival fluid samples will be collected using paper strips. these samples will be collected before and also two-months after oral treatment and will be analyzed by an immune-enzymatic test named elisa (enzyme-linked immunosorbent assay). in weekly sections, one trained specialist will performed treatment of gum diseases under local anesthesia using hand-instruments. researchers hypothesized that a) levels of defensins would be lower in the presence of periodontal disease when compared to a healthy periodontal condition; b) diabetes would influence production of these immune protective factors; and c) treatment would provide a greater beneficial amount of defensins.


Eligibility criteria:
inclusion criteria: * periodontally healthy individuals: at least 15 natural teeth, periodontal pocket depth (ppd) ≤ 3mm e absence of bleeding on probing. * periodontitis individuals: at least 15 natural teeth and at least 4 teeth with one or more periodontal sites showing combined ppd ≥ 4mm and clinical attachment level (cal) ≥ 3mm. * compensated diabetic individuals: compensated type 2 diabetes mellitus * decompensated diabetic individuals: decompensated type 2 diabetes mellitus (glycated hemoglobin hba1c \>7%) exclusion criteria: * past or actual systemic diseases other than diabetes type 2 in the diabetic groups * gingivitis * gingival overgrowth * necrotizing periodontal diseases * pregnant or lactating * smokers or former-smokers * medication that can influence periodontal status or host response to periodontal therapy * periodontal therapy in the past 6 months from baseline * use of systemic or local antibiotics or anti-inflammatory drugs within 3 months prior baseline

Keywords: beta-defensins chronic periodontitis diabetes mellitus non-surgical periodontal therapy
research study to look at how well cagrilintide together with semaglutide works in people with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this study looks at how well a new medicine called cagrilintide works together with semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide alone or semaglutide alone. before a new medicine can be prescribed to people it needs to be tested to see if it is safe and effective. participants will either get cagrilintide and semaglutide together or cagrilintide and a dummy medicine or semaglutide and a dummy medicine. which treatment participants get is decided by chance. a dummy medicine (placebo) looks like the study medicine but does not contain any active medicine. the dummy medicine is in the study to see if the study medicine works as expected. participants will get 2 injections per week on the same day. participants will take the study medicine with a pen. a pen is a medical tool with a needle used for injections under the skin. the study doctor or staff will show how. the study will last for about 39 weeks. participants will have 12 visits at the clinic and 5 phone calls with the study doctor. at 6 of the clinic visits participants must not eat and drink for 8 hours before the visit (water is allowed). women who can become pregnant cannot take part in this study. only women that are surgically sterilised or post-menopausal are allowed to participate in this study women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period


Eligibility criteria:
inclusion criteria: * female of non-childbearing potential or male * age above or equal to 18 years at the time of signing informed consent * body mass index (bmi) greater than or equal to 27.0 kg/m\^2 * diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before screening * glycated haemoglobin (hba1c) of 7.5-10.0% (58-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening * stable daily dose(s) ≥ 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at maximum tolerated or effective dose as judged by the investigator: metformin with or without sodium-glucose co-transporter-2 (sglt2) inhibitor exclusion criteria: * treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. however, short term insulin treatment for a maximum of 14 days and prior insulin treatment for gestational diabetes are allowed * renal impairment with estimated glomerular filtration rate (egfr) below 60 ml/min/1.73m\^2 by central laboratory at screening * uncontrolled and potentially unstable diabetic retinopathy or maculopathy. verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination